TMPase monoclonal antibody

Prostatic Acid Phosphatase (ACPP or PAP) is a member of the histidine acid phosphatase family. It is a non-specific phosphatase that is capable of dephosphorylating tyrosine residues as well as phospholipids under mildly acidic conditions. ACPP has ecto-5'-nucleotidase activity in pain-sensing neurons where it converts AMP to adenosine, suppressing the pain response. ACPP occurs as two isoforms that are both heavily glycosylated. The secreted phosphatase (sPAP) is found predominantly in the prostate and seminal plasma, while the cellular isoform (cPAP) is broadly expressed at very low levels and is associated with the plasma and lysosomal membranes. Cellular PAP has been shown to dephosphorylate ErbB2 at various tyrosine residues effectively terminating signaling. Furthermore, the physical interaction between cPAP and ErbB2 appears to regulate androgen sensitivity in prostate cancer cells. Loss of cPAP in androgen-sensitive prostate cancer cells results in the development of a castration-resistant phenotype suggesting that ACPP plays a significant role in prostate cancer cell growth. ACPP is expressed in metastatic cells arising from prostate cancer - especially in prostate-derived bone metastasis - suggesting that it may be a relevant diagnostic indicator of prostate cancer re-emergence in bone.

The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .